Search

Your search keyword '"Sargent, Carey"' showing total 82 results

Search Constraints

Start Over You searched for: Author "Sargent, Carey" Remove constraint Author: "Sargent, Carey" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
82 results on '"Sargent, Carey"'

Search Results

2. Picture My Gender(s): Using Interactive Media to Engage Students in Theories of Gender Construction

3. iMusic: Living and Working as Musicians in Digital Capitalism

6. Novartis May Raise Public Alcon Bid

10. Novartis, Human Genome join forces over hepatitis drug

11. Pfizer to pay up to $803M for rights to Incyte drugs

12. Generic copies of biotechnology drugs looming over market; Patents expiring for products with annual sales in the billions

15. Roche to purchase Disetronic, sell vitamins business

16. Serono purchases rights for drug to treat MS

17. Aventis net rises, but scales drop

20. Dentsply to pay $492.1 million for Dugussa AG's dental unit

21. UBS to publish preliminary earnings early

22. Ciba sidesteps price pressures as net rises 65%

23. DIY Musicians meet Web 2.0.

24. Local Musicians in the Age of Digital Reproduction.

25. Local Culture for Sale: Small Town Music Monopoly, Small Town Resistance.

26. Enacting Rock Authenticity in Music Stores.

27. Cultural Logic: Against Economic Determinism.

28. Forest Laboratories' Globe-Trotting Profits.

29. Commerzbank lifts its net income

30. Speedel makes its mark guiding drugs through testing stages: Five-year-old Swiss company thrives after pact with Novartis on blood-pressure medication

31. Roche swung to loss for 2002, cites heavy litigation charges

32. Strong currency expected to pressure Novartis results

33. Schering's menopause drug wins approval in Netherlands

34. OGS's first drug gets approval for EU market

35. Roche gets rights to some drugs from Antisoma

36. Aventis reports 21% rise in 3rd-quarter profit

37. Glaxo claims generics makers stole its secrets

38. Syngenta's profit up in 1st half on cost savings, lower taxes

39. Oxford GlycoSciences reaches marketing deal with Actelion

40. Serono posts a decline in net, lowers its full-year estimates

41. Pliva of Croatia agrees to buy a U.S. drug firm and its unit

42. Clariant has reduced its debt

43. Serono reports 5.2% increase in yearly profit

44. Schering will take a stake MorphoSys and fund research

45. BASF earnings disappoint as sales decline by 22%

46. Bayer to report weak results for third quarter

47. Serono posts sales below expectations for third quarter

48. Clariant's revenue falls on slowdown

49. Actelion nears launch of drug after U.S. regulatory action

50. Celanese again cuts earnings estimates for the full year

Catalog

Books, media, physical & digital resources